Zobrazeno 1 - 10
of 1 357
pro vyhledávání: '"M A Bethel"'
Autor:
M. Angelyn Bethel, Harald Sourij, Susanna R. Stevens, Karen Hannan, Yuliya Lokhnygina, Amanda I. Adler, Eric D. Peterson, Rury R. Holman, Renato D. Lopes
Publikováno v:
Cardiovascular Diabetology, Vol 22, Iss 1, Pp 1-7 (2023)
Abstract Background Estimating cardiovascular (CV) event accrual is important for outcome trial planning. Limited data exist describing event accrual patterns in patients with type 2 diabetes (T2D). We compared apparent CV event accrual patterns with
Externí odkaz:
https://doaj.org/article/f5e45fcdc3fd461992ea0fb964945617
Autor:
Ruth L. Coleman, Charles A. B. Scott, Zhihui Lang, M. Angelyn Bethel, Jaakko Tuomilehto, Rury R. Holman
Publikováno v:
Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-7 (2019)
Abstract Background Alpha-glucosidase inhibitors (AGIs) have been shown to reduce incident type 2 diabetes but their impact on cardiovascular (CV) disease remains controversial. We sought to identify the overall impact of AGIs with respect to inciden
Externí odkaz:
https://doaj.org/article/4b92b34490fa4cb3b672ed86acd45a80
Autor:
Paul Harrison, M. Angelyn Bethel, Irene Kennedy, Robert Dinsdale, Ruth Coleman, Rury R. Holman
Publikováno v:
Platelets, Vol 30, Iss 4, Pp 521-529 (2019)
The antiplatelet efficacy of aspirin (ASA) is reduced in type 2 diabetes (T2D). As the best ex vivo method of measuring ASA efficacy remains uncertain, we compared nine platelet function tests to assess responsiveness to three ASA dosing regimens in
Externí odkaz:
https://doaj.org/article/470be060714648b3ac5f6116cf1404cb
Autor:
Fernando Guerrero-Romero
Publikováno v:
New England Journal of Medicine. 360:549-549
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c3cdbfe90c4240651c0f1b2b3a867b9
https://doi.org/10.1056/nejmbkrev0805090
https://doi.org/10.1056/nejmbkrev0805090
Autor:
Kelley R.H. Branch, Gilles R. Dagenais, Alvaro Avezum, Jan Basile, Ignacio Conget, William C. Cushman, Petr Jansky, Mark Lakshmanan, Fernando Lanas, Lawrence A. Leiter, Prem Pais, Nana Pogosova, Peter J. Raubenheimer, Lars Ryden, Jonathan E. Shaw, Wayne H.H. Sheu, Theodora Temelkova‐Kurktschiev, M. Angelyn Bethel, Hertzel C. Gerstein, Ramasundarahettige Chinthanie, Jeffrey L. Probstfield
Publikováno v:
European Journal of Heart Failure. 24:1805-1812
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ac626ffc6207dd342aff9abcbbb627b
https://doi.org/10.1002/ejhf.2670
https://doi.org/10.1002/ejhf.2670
Autor:
Hertzel C. Gerstein, Shun-Fu Lee, Guillaume Paré, M. Angelyn Bethel, Helen M. Colhoun, Anastasia Hoover, Mark Lakshmanan, Yanzhu Lin, Valentino Pirro, Hui-Rong Qian, Giacomo Ruotolo, Lars Ryden, Jonathan M. Wilson, Kevin L. Duffin
OBJECTIVE The glucagon-like peptide-1 receptor agonist dulaglutide reduced MACE in the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial. This article expores the relationship of selected biomarkers to both dulagluti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2640ca757c8cf50993017da4bd7b9737
https://doi.org/10.2337/figshare.22120097
https://doi.org/10.2337/figshare.22120097
Autor:
Giulia Ferrannini, Juan M. Maldonado, Sohini Raha, Purnima Rao-Melacini, Rutaba Khatun, Charles Atisso, Linda Shurzinske, Hertzel C. Gerstein, Lars Rydén, M. Angelyn Bethel
Publikováno v:
Scandinavian Cardiovascular Journal. 57
Objectives. To assess whether the use of cardioprotective therapies for type 2 diabetes varies by gender and whether the risk of cardiovascular events is higher in women versus men in the REWIND trial, including an international type 2 diabetes patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d71bb0551b59f6718d31a47c413065a4
https://doi.org/10.1080/14017431.2023.2166101
https://doi.org/10.1080/14017431.2023.2166101
Autor:
Robert J. Mentz, M. Angelyn Bethel, Peter Merrill, Yuliya Lokhnygina, John B. Buse, Juliana C. Chan, João S. Felício, Shaun G. Goodman, Jasmine Choi, Stephanie M. Gustavson, Nayyar Iqbal, Renato D. Lopes, Aldo P. Maggioni, Peter Öhman, Neha J. Pagidipati, Neil R. Poulter, Ambady Ramachandran, Barry Reicher, Rury R. Holman, Adrian F. Hernandez
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 7, Iss 19 (2018)
Background In the EXSCEL (Exenatide Study of Cardiovascular Event Lowering), exenatide once‐weekly resulted in a nonsignificant reduction in major adverse cardiovascular events (MACEs) and a nominal 14% reduction in all‐cause mortality in 14 752
Externí odkaz:
https://doaj.org/article/0fea5ded97ad46fd8a2658707703a02e
Autor:
Simon J Griffin, M Angelyn Bethel, Rury R Holman, Kamlesh Khunti, Nicholas Wareham, Gwen Brierley, Melanie Davies, Andrew Dymond, Rose Eichenberger, Philip Evans, Alastair Gray, Colin Greaves, Kyla Harrington, Graham Hitman, Greg Irving, Sarah Lessels, Ann Millward, John R Petrie, Martin Rutter, Mike Sampson, Naveed Sattar, Stephen Sharp
Publikováno v:
Health Technology Assessment, Vol 22, Iss 18 (2018)
Background: The treatment of people with diabetes with metformin can reduce cardiovascular disease (CVD) and may reduce the risk of cancer. However, it is unknown whether or not metformin can reduce the risk of these outcomes in people with elevated
Externí odkaz:
https://doaj.org/article/3343c20bc7f54c8ca7a9cdd55705b78f
Autor:
Heike Jung, Manige Konig, Joanna Van, Jennifer Peleshok, Enzo Bonora, M. Angelyn Bethel, Sohini Raha, Juan P. Frias, David A. Cox, Jarrett Meyer
Publikováno v:
Diabetes Therapy
Background Gastrointestinal (GI) events are the most frequent treatment-emergent adverse events (TEAEs) reported for glucagon-like peptide-1 receptor agonist therapies. This post hoc analysis of the AWARD-11 phase 3 trial assessed the GI tolerability
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aac641853bbded93dd9b0088557106c9
https://doi.org/10.1007/s13300-021-01140-9
https://doi.org/10.1007/s13300-021-01140-9